Last 12 months
Inside the activity.
0 purchase rows · 28 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 7 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 13 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 10, 2026 13:22 UTC |
Michaelson JenniferChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001193125-26-387381 · ownership.xml · derivative · entry 3 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,987 Underlying: Common Stock · 4,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 13:22 UTC |
Michaelson JenniferChief Scientific Officer
|
SaleCommon Stock | 8,000 | $21.57 | $172,560.00 |
DisclosureSEC source: 0001193125-26-387381 · ownership.xml · nonDerivative · entry 2 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 158,844 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.31 to $21.83. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 13:22 UTC |
Michaelson JenniferChief Scientific Officer
|
Exercise / conversionCommon Stock | 4,000 | $4.30 | $17,200.00 |
DisclosureSEC source: 0001193125-26-387381 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 166,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2026 Filed Aug 14, 2026 21:00 UTC |
Michaelson JenniferChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001193125-26-352523 · ownership.xml · derivative · entry 3 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,987 Underlying: Common Stock · 30,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter. Read SEC document |
| August 13, 2026 Filed Aug 14, 2026 21:00 UTC |
Michaelson JenniferChief Scientific Officer
|
SaleCommon Stock | 30,000 | $20.26 | $607,800.00 |
DisclosureSEC source: 0001193125-26-352523 · ownership.xml · nonDerivative · entry 2 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,844 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.69. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 13, 2026 Filed Aug 14, 2026 21:00 UTC |
Michaelson JenniferChief Scientific Officer
|
Exercise / conversionCommon Stock | 30,000 | $4.30 | $129,000.00 |
DisclosureSEC source: 0001193125-26-352523 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 192,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2026 Filed Jul 7, 2026 21:00 UTC |
Michaelson JenniferChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001193125-26-297605 · ownership.xml · derivative · entry 3 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,987 Underlying: Common Stock · 4,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter. Read SEC document |
| July 06, 2026 Filed Jul 7, 2026 21:00 UTC |
Michaelson JenniferChief Scientific Officer
|
SaleCommon Stock | 8,000 | $17.82 | $142,560.00 |
DisclosureSEC source: 0001193125-26-297605 · ownership.xml · nonDerivative · entry 2 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,844 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.35 to $18.19. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 06, 2026 Filed Jul 7, 2026 21:00 UTC |
Michaelson JenniferChief Scientific Officer
|
Exercise / conversionCommon Stock | 4,000 | $4.30 | $17,200.00 |
DisclosureSEC source: 0001193125-26-297605 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 21:00 UTC |
Fenton Mary KayChief Financial Officer
|
GrantCommon Stock | 1,541 | $8.60 | $13,252.60 |
DisclosureSEC source: 0001193125-26-294863 · ownership.xml · nonDerivative · entry 1 Fenton Mary Kay · CIK 0001378589 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,921 F1 · kind: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the "ESPP"), for the purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on January 2, 2026. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 21:00 UTC |
SUMER JACQUELYN LChief Legal Officer
|
GrantCommon Stock | 2,470 | $8.60 | $21,242.00 |
DisclosureSEC source: 0001193125-26-294869 · ownership.xml · nonDerivative · entry 1 SUMER JACQUELYN L · CIK 0001844824 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,559 F1 · kind: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the "ESPP"), for the purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on January 2, 2026. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 21:00 UTC |
Rosenberg AnthonyDirector
|
GrantStock Option (Right to Buy) · Derivative | 25,319 | $0.00 Strike: $13.55 | $0.00 |
DisclosureSEC source: 0001193125-26-276060 · ownership.xml · derivative · entry 1 Rosenberg Anthony · CIK 0001466175 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,319 Underlying: Common Stock · 25,319 shares Expires 2026-06-16 F1 · derivative.exercise_date: The option represents a right to purchase a total of 25,319 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 21:00 UTC |
Webster Stephen WDirector
|
GrantStock Option (Right to Buy) · Derivative | 25,319 | $0.00 Strike: $13.55 | $0.00 |
DisclosureSEC source: 0001193125-26-276057 · ownership.xml · derivative · entry 1 Webster Stephen W · CIK 0001438421 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,319 Underlying: Common Stock · 25,319 shares Expires 2026-06-16 F1 · derivative.exercise_date: The option represents a right to purchase a total of 25,319 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 21:00 UTC |
Thistle MaryDirector
|
GrantStock Option (Right to Buy) · Derivative | 25,319 | $0.00 Strike: $13.55 | $0.00 |
DisclosureSEC source: 0001193125-26-276055 · ownership.xml · derivative · entry 1 Thistle Mary · CIK 0001317917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,319 Underlying: Common Stock · 25,319 shares Expires 2026-06-16 F1 · derivative.exercise_date: The option represents a right to purchase a total of 25,319 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 21:00 UTC |
Allen Andrew RDirector
|
GrantStock Option (Right to Buy) · Derivative | 21,781 | $0.00 Strike: $13.55 | $0.00 |
DisclosureSEC source: 0001193125-26-276056 · ownership.xml · derivative · entry 1 Allen Andrew R · CIK 0001374539 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,781 Underlying: Common Stock · 21,781 shares Expires 2026-06-16 F1 · derivative.exercise_date: The option represents a right to purchase a total of 21,781 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 21:00 UTC |
Meek David D.Director
|
GrantStock Option (Right to Buy) · Derivative | 25,319 | $0.00 Strike: $13.55 | $0.00 |
DisclosureSEC source: 0001193125-26-276059 · ownership.xml · derivative · entry 1 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,319 Underlying: Common Stock · 25,319 shares Expires 2026-06-16 F1 · derivative.exercise_date: The option represents a right to purchase a total of 25,319 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 21:00 UTC |
Doyle MittieDirector
|
GrantStock Option (Right to Buy) · Derivative | 21,781 | $0.00 Strike: $13.55 | $0.00 |
DisclosureSEC source: 0001193125-26-276054 · ownership.xml · derivative · entry 1 Doyle Mittie · CIK 0001918845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,781 Underlying: Common Stock · 21,781 shares Expires 2026-06-16 F1 · derivative.exercise_date: The option represents a right to purchase a total of 21,781 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date. Read SEC document |
| May 05, 2026 Filed May 6, 2026 21:00 UTC |
Michaelson JenniferChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001193125-26-209307 · ownership.xml · derivative · entry 4 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,987 Underlying: Common Stock · 4,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter. Read SEC document |
| May 05, 2026 Filed May 6, 2026 21:00 UTC |
Michaelson JenniferChief Scientific Officer
|
SaleCommon Stock | 200 | $15.58 | $3,116.00 |
DisclosureSEC source: 0001193125-26-209307 · ownership.xml · nonDerivative · entry 3 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 166,844 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.56 to $15.60. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 05, 2026 Filed May 6, 2026 21:00 UTC |
Michaelson JenniferChief Scientific Officer
|
SaleCommon Stock | 7,800 | $14.60 | $113,880.00 |
DisclosureSEC source: 0001193125-26-209307 · ownership.xml · nonDerivative · entry 2 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 167,044 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.24 to $15.12. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 05, 2026 Filed May 6, 2026 21:00 UTC |
Michaelson JenniferChief Scientific Officer
|
Exercise / conversionCommon Stock | 4,000 | $4.30 | $17,200.00 |
DisclosureSEC source: 0001193125-26-209307 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 174,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 21:00 UTC |
Michaelson JenniferChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001193125-26-098781 · ownership.xml · derivative · entry 3 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,987 Underlying: Common Stock · 4,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 21:00 UTC |
Michaelson JenniferChief Scientific Officer
|
SaleCommon Stock | 8,000 | $15.68 | $125,440.00 |
DisclosureSEC source: 0001193125-26-098781 · ownership.xml · nonDerivative · entry 2 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,844 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.38 to $16.31. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 21:00 UTC |
Michaelson JenniferChief Scientific Officer
|
Exercise / conversionCommon Stock | 4,000 | $4.30 | $17,200.00 |
DisclosureSEC source: 0001193125-26-098781 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 22:05 UTC |
Michaelson JenniferChief Scientific Officer
|
SaleCommon Stock | 1,780 | $14.14 | $25,169.20 |
DisclosureSEC source: 0001193125-26-077259 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 174,844 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.89 to $14.35. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 22:00 UTC |
AHMED NADIMDirector · President and CEO
|
SaleCommon Stock | 13,515 | $14.47 | $195,562.05 |
DisclosureSEC source: 0001193125-26-072001 · ownership.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,803 F1 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 22:00 UTC |
Michaelson JenniferChief Scientific Officer
|
SaleCommon Stock | 3,601 | $14.47 | $52,106.47 |
DisclosureSEC source: 0001193125-26-072002 · ownership.xml · nonDerivative · entry 2 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 176,624 F3 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 22:00 UTC |
Jones Jeffrey AlanChief Medical Officer
|
SaleCommon Stock | 4,582 | $14.47 | $66,301.54 |
DisclosureSEC source: 0001193125-26-072000 · ownership.xml · nonDerivative · entry 1 Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,968 F1 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 22:00 UTC |
SUMER JACQUELYN LChief Legal Officer
|
SaleCommon Stock | 3,601 | $14.47 | $52,106.47 |
DisclosureSEC source: 0001193125-26-071997 · ownership.xml · nonDerivative · entry 1 SUMER JACQUELYN L · CIK 0001844824 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,089 F1 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 22:00 UTC |
Michaelson JenniferChief Scientific Officer
|
SaleCommon Stock | 1,752 | $13.99 | $24,510.48 |
DisclosureSEC source: 0001193125-26-072002 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 180,225 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.68 to $14.31. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 22:00 UTC |
Fenton Mary KayChief Financial Officer
|
SaleCommon Stock | 4,398 | $13.62 | $59,900.76 |
DisclosureSEC source: 0001193125-26-064261 · ownership.xml · nonDerivative · entry 1 Fenton Mary Kay · CIK 0001378589 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,380 F1 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 22:00 UTC |
AHMED NADIMDirector · President and CEO
|
SaleCommon Stock | 16,381 | $13.62 | $223,109.22 |
DisclosureSEC source: 0001193125-26-064254 · ownership.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 404,318 F1 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 22:00 UTC |
Jones Jeffrey AlanChief Medical Officer
|
SaleCommon Stock | 4,982 | $13.62 | $67,854.84 |
DisclosureSEC source: 0001193125-26-064257 · ownership.xml · nonDerivative · entry 1 Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,550 F1 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 22:00 UTC |
SUMER JACQUELYN LChief Legal Officer
|
SaleCommon Stock | 3,742 | $13.62 | $50,966.04 |
DisclosureSEC source: 0001193125-26-064255 · ownership.xml · nonDerivative · entry 1 SUMER JACQUELYN L · CIK 0001844824 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,690 F1 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 22:00 UTC |
Michaelson JenniferChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001193125-26-064256 · ownership.xml · derivative · entry 4 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,987 Underlying: Common Stock · 8,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 22:00 UTC |
Michaelson JenniferChief Scientific Officer
|
SaleCommon Stock | 8,000 | $14.30 | $114,400.00 |
DisclosureSEC source: 0001193125-26-064256 · ownership.xml · nonDerivative · entry 3 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,977 F2 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 22:00 UTC |
Michaelson JenniferChief Scientific Officer
|
Exercise / conversionCommon Stock | 8,000 | $4.30 | $34,400.00 |
DisclosureSEC source: 0001193125-26-064256 · ownership.xml · nonDerivative · entry 2 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 189,977 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 22:00 UTC |
Michaelson JenniferChief Scientific Officer
|
SaleCommon Stock | 3,742 | $13.62 | $50,966.04 |
DisclosureSEC source: 0001193125-26-064256 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,977 F1 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 22:00 UTC |
Fenton Mary KayChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 137,500 | $0.00 Strike: $12.44 | $0.00 |
DisclosureSEC source: 0001193125-26-059637 · ownership.xml · derivative · entry 2 Fenton Mary Kay · CIK 0001378589 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,500 Underlying: Common Stock · 137,500 shares Expires 2036-02-18 F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 22:00 UTC |
Fenton Mary KayChief Financial Officer
|
GrantCommon Stock | 68,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-059637 · ownership.xml · nonDerivative · entry 1 Fenton Mary Kay · CIK 0001378589 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,778 F1 · shares: The shares underlying the restricted stock unit vest on an annual basis over four years. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 22:00 UTC |
AHMED NADIMDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 828,000 | $0.00 Strike: $12.44 | $0.00 |
DisclosureSEC source: 0001193125-26-059639 · ownership.xml · derivative · entry 1 AHMED NADIM · CIK 0001731193 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 828,000 Underlying: Common Stock · 828,000 shares Expires 2036-02-18 F1 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 22:00 UTC |
SUMER JACQUELYN LChief Legal Officer
|
GrantStock Option (Right to Buy) · Derivative | 230,000 | $0.00 Strike: $12.44 | $0.00 |
DisclosureSEC source: 0001193125-26-059641 · ownership.xml · derivative · entry 1 SUMER JACQUELYN L · CIK 0001844824 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2036-02-18 F1 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 22:00 UTC |
Savill CorrineChief Business Officer
|
GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $12.44 | $0.00 |
DisclosureSEC source: 0001193125-26-059638 · ownership.xml · derivative · entry 1 Savill Corrine · CIK 0001837524 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2036-02-18 F1 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 22:00 UTC |
Jones Jeffrey AlanChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $12.44 | $0.00 |
DisclosureSEC source: 0001193125-26-059640 · ownership.xml · derivative · entry 1 Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2036-02-18 F1 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 22:00 UTC |
Michaelson JenniferChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 115,000 | $0.00 Strike: $12.44 | $0.00 |
DisclosureSEC source: 0001193125-26-059636 · ownership.xml · derivative · entry 2 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2036-02-18 F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 22:00 UTC |
Michaelson JenniferChief Scientific Officer
|
GrantCommon Stock | 57,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-059636 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,719 F1 · shares: The shares underlying the restricted stock unit vest on an annual basis over four years. Read SEC document |
| February 12, 2026 Filed Feb 13, 2026 22:00 UTC |
Michaelson JenniferChief Scientific Officer
|
SaleCommon Stock | 416 | $12.03 | $5,004.48 |
DisclosureSEC source: 0001193125-26-051700 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,219 F1 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| January 22, 2026 Filed Jan 23, 2026 22:00 UTC |
Michaelson JenniferChief Scientific Officer
|
SaleCommon Stock | 4,000 | $12.30 | $49,200.00 |
DisclosureSEC source: 0001193125-26-021225 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,635 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 22:01 UTC |
Fenton Mary KayChief Financial Officer
|
GrantCommon Stock | 27 | $6.49 | $175.23 |
DisclosureSEC source: 0001193125-26-002687 · ownership.xml · nonDerivative · entry 1 Fenton Mary Kay · CIK 0001378589 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,028 F1 · kind: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the "ESPP"), for the purchase period of July 1, 2025 through December 31, 2025. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on July 1, 2025. F3 · balance_after: Includes 2,001 shares of common stock that the Reporting Person purchased pursuant to the Issuer's 2021 Employee Stock Purchase Plan for the purchase period of January 1, 2025 through June 30, 2025 that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 22:00 UTC |
AHMED NADIMDirector · President and CEO
|
SaleCommon Stock | 9,922 | $10.01 | $99,319.22 |
DisclosureSEC source: 0001193125-25-335482 · ownership.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 420,699 F1 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.